high-angle-woman-interacting-with-plasma-ball_23-2150572305

THE JOHNS HOPKINS CENTER OF PSYCHEDELIC AND CONSCIOUSNESS RESEARCH

by Research

Johns Hopkins is a well-known and highly credible resource for studies involving most any medical or mental health research.  The Johns Hopkins Center of Psychedelic and Consciousness Research is a leader taking on the current research into the use of psychedelic substances for mental health concerns.

“Backed by $55 million in funding, researchers build on previous work and expand research on psychedelics for illness and wellness: (1) to develop new treatments for a wider variety of psychiatric and behavioral disorders with the aspiration of treatments tailored to the specific needs of individual patients and (2) to expand research in healthy volunteers with the ultimate aspiration of opening new ways to support human thriving.”

Included is the link for Johns Hopkins Medicine is dedicated to the current timeline with Psychedelics Research and Psilocybin Therapy.  This timeline gives you easy access to many of the research papers and news releases across the history of JH research into psychedelics use for mental health concerns.

Johns Hopkins Center for Psychedelic and Consciousness Research (hopkinsmedicine.org)

distressed-woman-with-pills-table-concept-reflects-struggles-with-health-medication

THE NATIONAL INSTITUTE OF HEALTH (NIH) STUDIES DATA ON THE EFFECTS OF KETAMINE FOR MENTAL HEALTH ISSUES

by Research

“Currently, ketamine is used in treating multiple pain, mental health, and substance abuse disorders due to rapid-acting analgesic and antidepressant effects. Its limited short-term durability has motivated research into the potential synergistic actions between ketamine and psychotherapy to sustain benefits.”

“The use of Ketamine Assisted Psychotherapy (KAP) can potentially fulfil the unmet clinical need for an effective treatment for multiple complex and often comorbid pain, psychological, and substance use disorders. Ketamine’s demonstrated ability to produce antidepressant and anxiolytic effects likely interacts with the processes involved in psychotherapy, ideally as a conduit for rapid-change, increasing treatment engagement and adherence, building the therapeutic alliance, and lowering defensiveness by providing reprieves from distressing symptomology while inducing transpersonal experiences at higher doses.”

You can read the entire research study here:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207256